AI assistant
Apellis Pharmaceuticals, Inc. — Director's Dealing 2018
Nov 16, 2018
31417_dirs_2018-11-15_21e2b8d0-212e-4756-8d06-11a7c4cdcf75.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2018-11-14
Reporting Person: Axon Steven (Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-14 | Common Stock | M | 11500 | $2.59 | Acquired | 50110 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-11-14 | Stock Option (Right to Buy) | $2.59 | M | 11500 | Disposed | 2027-05-17 | Common Stock (11500) | Direct |
Footnotes
F1: This option was granted on May 18, 2017 and has vested as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.
F2: This option was granted on May 18, 2017 and will vest as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.